IGF-1 DES vs IGF-1 LR3
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: des(1-3)IGF-1, Des(1-3) IGF-I
IGF-1 DES is insulin-like growth factor 1 with its first three amino acids chopped off, leaving a 67-residue peptide. That small cut makes it bind poorly to the IGF binding proteins that normally keep IGF-1 in check, so more of it reaches the receptor and it acts stronger, but shorter. It occurs naturally in small amounts (it was first isolated from human fetal brain tissue) and is sold online as a muscle-building research peptide. There are no human trials of it at all, so everything said about it in people is extrapolation.
Also: Long R3 IGF-1, LR3
IGF-1 LR3 is a modified version of insulin-like growth factor 1, engineered to last far longer in the body than the natural hormone. It is popular in physique circles and it is worth being blunt about the evidence: there are effectively no human clinical trials of this specific analog. Everything below the mechanism section is preclinical work, laboratory use, or community reporting.
Key Comparison Insights
- Both peptides belong to the Growth Hormone category, suggesting similar primary applications.
Detailed Comparison
| Attribute | IGF-1 DES | IGF-1 LR3 |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Like regular IGF-1, des(1-3)IGF-1 activates the type 1 IGF receptor, a tyrosine kinase receptor closely related to the insulin receptor. That switches on PI3K/Akt and MAPK signalling, which drives cell growth, protein synthesis and glucose uptake. The difference is the binding proteins. In the body almost all IGF-1 rides around bound to IGFBPs, which limit how much can hit the receptor. Removing the N-terminal tripeptide (Gly-Pro-Glu) sharply weakens IGFBP binding while leaving receptor binding intact. In a 1992 JCI study on rat granulosa cells, des(1-3)IGF-1 was about 10 times more potent than intact IGF-1 when binding proteins were present, and roughly equal once they were removed, which shows the extra potency comes from dodging the binding proteins rather than a stronger receptor hit. The trade-off: unbound IGF-1 is cleared fast, so its action is short and local, which is why people inject it into a specific muscle. It also carries IGF-1's insulin-like effect on blood sugar. | Natural IGF-1 is almost entirely bound up by IGF binding proteins in circulation, which controls how much is active and gives it a half-life measured in minutes. LR3 makes two changes: an arginine substitution at position 3, and a 13-amino-acid extension on the N-terminus. Together these dramatically reduce binding-protein affinity, so far more of the molecule stays free and active, extending the functional half-life to something on the order of a day rather than minutes. Once free, it activates the IGF-1 receptor, driving protein synthesis, satellite cell activation and cell proliferation in muscle. That same lack of binding-protein regulation is the reason for caution: binding proteins are a control mechanism, and removing the control is the point of the drug and also its main risk. |
| Common Dosing | Community-reported 20-100 mcg per day Usually once daily on training days | 20-50 mcg daily Once daily |
| Administration | Intramuscular or subcutaneous injection (community practice); studied by injection in animals only | Subcutaneous injection. Because of the hypoglycemia risk, timing relative to carbohydrate intake is the main practical consideration reported. |
| Typical Duration | Community reports describe short cycles of about 4-6 weeks; there is no human data on safe duration | Community cycles are typically reported as 4-6 weeks, on the reasoning that receptor downregulation follows longer use |
| Best Time to Take | Around training, per community practice | With or near a carbohydrate-containing meal |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The research is old, small, and entirely in cells and animals. Sara, Carlsson-Skwirut and colleagues isolated a truncated variant of IGF-1 from human fetal brain in 1986 (PNAS). In GH-deficient lit/lit mice, Gillespie and colleagues (J Endocrinol, 1990) found that 3 microgram daily injections of des(1-3)IGF-1 increased body length about as much as 30 micrograms of regular IGF-1, confirming its higher potency in a living animal; organ weights (kidney, heart) also rose. Adashi and colleagues (JCI, 1992) showed the roughly 10-fold potency gain disappears when IGF binding proteins are removed. Beyond that, it is mostly a lab tool for studying the IGF system. There are no human trials, no pharmacokinetic data in people, and no safety data. Claims about local muscle hyperplasia, fat loss, or recovery are bodybuilding lore built on IGF-1 biology, not on studies of this peptide. Theoretical risks are the same as for IGF-1 and other analogues: low blood sugar, and long-term concerns about feeding the growth of existing tumours, since IGF-1 signalling is a known growth pathway in several cancers. Quality is another unknown: the material sold online has no pharmaceutical oversight. | IGF-1 LR3 was developed as a cell culture reagent, and that remains its principal legitimate use: it is sold to laboratories to promote cell growth in bioreactors. There are no published randomized human trials of IGF-1 LR3 for muscle growth, body composition or performance. The animal and in vitro work does show what you would expect, increased protein synthesis and muscle cell proliferation, and there is a genuine human literature on recombinant IGF-1 (mecasermin) for severe IGF-1 deficiency, but mecasermin is a different molecule with different pharmacokinetics and its trial data should not be read across. The two consistent safety themes in the underlying biology are hypoglycemia, because IGF-1 has meaningful cross-reactivity with the insulin receptor, and the theoretical concern that chronically elevated IGF-1 signalling promotes growth of tissue you did not intend to grow, including existing tumors. |
Frequently Asked Questions: IGF-1 DES vs IGF-1 LR3
What is the difference between IGF-1 DES and IGF-1 LR3?
IGF-1 DES is a growth hormone peptide that igf-1 des is insulin-like growth factor 1 with its first three amino acids chopped off, leaving a 67-residue peptide. that small cut makes it bind poorly to the igf binding proteins that normally keep igf-1 in check, so more of it reaches the receptor and it acts stronger, but shorter. it occurs naturally in small amounts (it was first isolated from human fetal brain tissue) and is sold online as a muscle-building research peptide. there are no human trials of it at all, so everything said about it in people is extrapolation. IGF-1 LR3 is a growth hormone peptide that igf-1 lr3 is a modified version of insulin-like growth factor 1, engineered to last far longer in the body than the natural hormone. it is popular in physique circles and it is worth being blunt about the evidence: there are effectively no human clinical trials of this specific analog. everything below the mechanism section is preclinical work, laboratory use, or community reporting. The main differences lie in their mechanisms of action and clinical applications.
Which is better, IGF-1 DES or IGF-1 LR3?
Neither is universally "better" - the choice depends on your specific goals. IGF-1 DES is typically used for growth hormone purposes, while IGF-1 LR3 is used for growth hormone. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can IGF-1 DES and IGF-1 LR3 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using IGF-1 DES and IGF-1 LR3 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.